HRAS Human

V-Ha-ras Harvey Rat Sarcoma Viral Oncogene Homolog Human Recombinant

Cat. No.

BT15131

Source

Escherichia Coli.

Synonyms

C-BAS/HAS, C-H-RAS, C-HA-RAS1, CTLO, H-RASIDX, HAMSV, HRAS1, K-RAS, N-RAS, RASH1.

Appearance

Sterile filtered colorless solution.

Purity

Greater than 90% as determined by SDS-PAGE.

Usage

THE BioTek's products are furnished for LABORATORY RESEARCH USE ONLY. They may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.

Shipped with Ice Packs

In Stock

Quick Inquiry

Description

HRAS Human Recombinant produced in E.Coli is a single, non-glycosylated, polypeptide chain containing 194 amino acids (1-186 a.a.) and having a molecular mass of 22 kDa. HRAS protein is fused to an 8 amino acid His-Tag at C-terminus and purified by standard chromatography.

Product Specs

Introduction

HRAS, a member of the Ras oncogene family, shares similarities with the transforming genes found in mammalian sarcoma retroviruses. These genes encode proteins involved in signal transduction pathways. These proteins exhibit the ability to bind both GTP and GDP and possess intrinsic GTPase activity. HRAS undergoes a continuous cycle of palmitoylation and depalmitoylation, facilitating its rapid movement between the plasma membrane and the Golgi apparatus. Mutations in HRAS are linked to Costello syndrome, a disorder characterized by excessive prenatal growth, postnatal growth retardation, increased susceptibility to tumor development, intellectual disabilities, skin and musculoskeletal abnormalities, distinctive facial features, and cardiovascular defects. Abnormalities in the HRAS gene are implicated in various cancers, including bladder cancer, follicular thyroid cancer, and oral squamous cell carcinoma.

Description

Recombinant Human HRAS, expressed in E. coli, is a single, non-glycosylated polypeptide chain consisting of 194 amino acids (residues 1-186). This protein has a molecular weight of 22 kDa. An 8-amino acid His-tag is fused to the C-terminus of the HRAS protein, which is purified using standard chromatographic techniques.

Physical Appearance

A clear, colorless solution that has been sterilized by filtration.

Formulation

A solution at a concentration of 0.5 mg/ml containing 20 mM Tris-HCl (pH 8), 0.1 M NaCl, and 20% glycerol.

Stability

For short-term storage (2-4 weeks), keep refrigerated at 4°C. For extended storage, freeze at -20°C. Adding a carrier protein (0.1% HSA or BSA) is advisable for long-term storage. Repeated freezing and thawing should be avoided.

Purity

Purity exceeds 90% as determined by SDS-PAGE analysis.

Synonyms

C-BAS/HAS, C-H-RAS, C-HA-RAS1, CTLO, H-RASIDX, HAMSV, HRAS1, K-RAS, N-RAS, RASH1.

Source

Escherichia Coli.

Amino Acid Sequence

MTEYKLVVVG AGGVGKSALT IQLIQNHFVD EYDPTIEDSY RKQVVIDGET CLLDILDTAG QEEYSAMRDQ YMRTGEGFLC VFAINNTKSF EDIHQYREQI KRVKDSDDVP MVLVGNKCDL AARTVESRQA QDLARSYGIP YIETSAKTRQ GVEDAFYTLV REIRQHKLRK LNPPDESGPG CMSCKCLEHH HHHH.

Product Science Overview

Discovery and Nomenclature

The HRAS gene was first identified in the early 1960s by J. J. Harvey, who discovered the Harvey strain of murine sarcoma virus (HaMSV) in rats. The viral oncogene, v-Ha-ras, was found to be homologous to the cellular proto-oncogene, c-Ha-ras, which is present in humans. The human homolog of this gene is located on the short arm of chromosome 11 at position 15.5 (11p15.5).

Function and Mechanism

HRAS encodes a protein known as p21ras, which functions as a molecular switch in various signal transduction pathways. This protein is involved in regulating cell division in response to growth factor stimulation. The HRAS protein binds to guanosine triphosphate (GTP) in its active state and possesses intrinsic GTPase activity, which allows it to hydrolyze GTP to guanosine diphosphate (GDP), thereby turning itself off.

The activation and inactivation of HRAS are tightly regulated by accessory proteins such as GTPase-activating proteins (GAPs) and guanine nucleotide exchange factors (GEFs). GAPs accelerate the hydrolysis of GTP to GDP, while GEFs facilitate the exchange of GDP for GTP, thus reactivating HRAS.

Role in Cancer

Mutations in the HRAS gene can lead to its constitutive activation, resulting in uncontrolled cell proliferation and tumor formation. Such mutations are implicated in various types of cancers, including bladder cancer, follicular thyroid cancer, and oral squamous cell carcinoma. HRAS is one of the three major Ras genes, along with KRAS and NRAS, that are frequently mutated in human cancers.

Clinical Significance

The HRAS gene is also associated with several genetic disorders. For instance, mutations in HRAS cause Costello syndrome, a condition characterized by distinctive facial features, developmental delays, and an increased risk of tumor formation. Understanding the function and regulation of HRAS is crucial for developing targeted therapies for cancers and other diseases associated with its mutations.

Research and Therapeutic Approaches

Ongoing research aims to develop inhibitors that specifically target the HRAS protein and its downstream signaling pathways. These therapeutic approaches hold promise for treating cancers driven by HRAS mutations. Additionally, recombinant forms of the HRAS protein are used in various experimental settings to study its function and interactions with other cellular proteins.

Quick Inquiry

Personal Email Detected

Please use an institutional or corporate email address for inquiries. Personal email accounts ( such as Gmail, Yahoo, and Outlook) are not accepted. *

Name*

Email*

Phone

Country

Product Name

Quantity&Size*

Message

HRAS Human

Description

Product Specs

Product Science Overview

Quick Inquiry

Category

Service